First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Bevacizumab in combination with chemotherapy represents a standard of care for first-line
treatment in patients with advanced colorectal cancer. Molecular predictive factors for
bevacizumab efficacy have not yet been identified therefore selection of patients more likely
to benefit from such a treatment approach is not possible. Retrospective analyses suggested
that LDH serum levels may influence the clinical activity of anti-angiogenetic drugs. Primary
aim of our clinical trial will be to prospectively ascertain whether bevacizumab in
combination with chemotherapy has an improved clinical activity in patients with high LDH
serum levels compared to patients with normal LDH serum levels
Phase:
Phase 2
Details
Lead Sponsor:
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente